Novogenia AG, an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in partnership with 10X Health, expands their joint product pipeline and enhances their international collaboration in genetic analysis and longevity. Methylation, a fundamental biochemical process involved in numerous metabolic and regulatory functions, can significantly influence the processing of vitamins, neurotransmitters, and other biological molecules. While existing commercial tests typically analyze a limited set of genes, MGT Plus covers 27 genes, providing a more comprehensive view of methylation across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This broader scope offers more precise insights into key biochemical processes, enabling more personalized prevention and health strategies.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the significance of this advancement: “With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health.”
The global direct-to-consumer testing market is experiencing robust growth, reaching approximately $4.7 billion in 2025 and projected to exceed $16.0 billion by 2033. Genetic testing represents the largest segment, accounting for over 40% of the market. North America, with around 50% of global market volume in 2025, is a leading region, driven by growing interest in personalized health information and prevention.
Novogenia, headquartered in Munich, Germany, operates its own laboratory for genetic analyses used in disease diagnosis, treatment, and prevention, as well as in the production of tailored nutritional supplements and cosmetics. The company partners with healthcare professionals to optimize patient care based on genetic predispositions. Novogenia also holds investments in innovative biotech and life sciences companies.
This launch underscores Novogenia's strategic focus on expanding its international footprint and capitalizing on the increasing demand for personalized health solutions. By broadening its product portfolio with the MGT Plus test, Novogenia aims to provide more comprehensive genetic insights, potentially setting new standards in methylation analysis and preventive healthcare.
